UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

The Global NASH Congress – Slide release

An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.

Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.

Targeting Different Pathways of NASH Pathogenesis Using Simple and Combination Therapies
 

NASH pathogenesis involves multiple pathways of liver injury and disease progression – metabolic dysregulations, inflammatory
signaling, hepatocyte ballooning and apoptosis, liver fibrosis.

View the slides

Body Composition in NASH Clinical Trials
While BMI provides a rough estimate of how over- or under-weight a person is, it doesn’t tell you what portion of the weight is
muscle or fat, nor how these different tissue types are affected by treatment.                                                                                                           
View the slides
Liver biopsy as the Gold Standard for Diagnosis

Histological liver damages in NAFLD are the consequence of a complex association of several pathophysiological mechanisms
that can lead to cirrhosis and end-stage liver disease.

View the slides

Want to read more on NASH? Good news! We regularly update our blog with relevant articles, why not take a look at NASH – The Silent Killer You’ve Never Heard Of?

Leave a Reply

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive